Sharpen that needle

Archives of Neurology

Volumn 67, Issue 8, 2010, Pages 918-920

  Herskovits, A Zara ^a   Growdon, John H ^b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; FLUORODEOXYGLUCOSE F 18; TAU PROTEIN;

ALZHEIMER DISEASE; CEREBROSPINAL FLUID ANALYSIS; CREUTZFELDT JAKOB DISEASE; EDITORIAL; EPISODIC MEMORY; HUMAN; LUMBAR PUNCTURE; MILD COGNITIVE IMPAIRMENT; NEUROFIBRILLARY TANGLE; NEUROIMAGING; NEUROPATHOLOGY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SENILE PLAQUE; SENSITIVITY AND SPECIFICITY; STROKE;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; BIOPSY, NEEDLE; COGNITION DISORDERS; HUMANS; PEPTIDE FRAGMENTS; TAU PROTEINS;

EID: 77955462847     PISSN: 00039942     EISSN: 15383687     Source Type: Journal    
DOI: 10.1001/archneurol.2010.151     Document Type: Editorial

References (12)

1. De Meyer G, Shapiro F, Vanderstichele H, et al. Diagnosis-independent Alzheimer disease biomarker signature in cognitively normal elderly people. Arch Neurol. 2010;67(8):949-956.
2. Craig-Schapiro R, Fagan AM, Holtzman DM. Biomarkers of Alzheimer's disease. Neurobiol Dis. 2009;35(2):128-140.
3. Mattsson N, Zetterberg H, Hansson O, et al. CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. JAMA. 2009;302(4):385-393.
4. Ronald and Nancy Reagan Research Institute of the Alzheimer's Association and the National Institute on Aging Working Group. Consensus report of the working group on molecular and biochemical markers of Alzheimer's disease. Neurobiol Aging. 1998;19(2):109-116.
5. Tapiola T, Alafuzoff I, Herukka SK, et al. Cerebrospinal fluid β-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain. Arch Neurol. 2009;66(3):382-389.
6. Shaw LM, Vanderstichele H, Knapik-Czajka M, et al; Alzheimer's Disease Neuroimaging Initiative. Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Ann Neurol. 2009;65(4):403-413.
7. Bacskai BJ, Frosch MP, Freeman SH, et al. Molecular imaging with Pittsburgh Compound B confirmed at autopsy: a case report. Arch Neurol. 2007;64(3):431-434. (Pubitemid 46425701)
8. 42 in humans. Ann Neurol. 2006;59(3):512-519.
9. Dubois B, Feldman H, Jacova C, et al. Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol. 2007;6(8):734-746. (Pubitemid 47058377)
10. 42 ratio as a prediction of cognitive decline in nondemented older adults. Arch Neurol. 2007;64(3):343-349.
11. Jack CR Jr, Knopman DS, Jagust WJ, et al. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol. 2010;9(1):119-128.
12. Snider BJ, Fagan AM, Roe C, et al. Cerebrospinal fluid biomarkers and rate of cognitive decline in very mild dementia of the Alzheimer type. Arch Neurol. 2009;66(5):638-645.